Based in Rehovot, Israel, Kamada Ltd. manufactures and distributes plasma-derived protein therapeutics and specialty biopharmaceutical products. The company's core manufactured portfolio includes immunoglobulins and antiserums such as KAMRAB/KEDRAB for rabies prophylaxis, CYTOGAM for cytomegalovirus prevention in transplant recipients, VARIZIG for varicella post-exposure prophylaxis, and HEPAGAM B for hepatitis B prevention. Additional therapeutic areas include immune thrombocytopenic purpura treatment via WINRHO SDF, alpha-1 antitrypsin deficiency management through GLASSIA, and specialized antivenoms for snake bite treatment.
The company operates a dual revenue model combining proprietary manufactured products with a distribution business focused on the Israeli market. The distribution segment includes respiratory therapeutics such as BRAMITOB and FOSTER, immunological products including IVIG and various factor concentrates for hemophilia, rare disease treatments like PROCYSBI for cystinosis and LAMZEDE for alpha-mannosidosis, and oncology products including ELIGARD and BEVACIZUMAB KAMADA. This portfolio spans immunology, ophthalmology, respiratory, rare diseases, and oncology indications.
Kamada operates with approximately 420 full-time employees and generates revenues across North American, European, and Israeli markets. The company trades on Nasdaq and maintains a market capitalization of approximately $0.5 billion.
No 10-K filings found.